Compare Newegg Commerce Inc (NEGG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Recursion Pharmaceuticals Inc — how do they compare? Newegg Commerce Inc trades at $18.96 (market cap $398.29M), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.5× Newegg Commerce Inc's market cap. Which is the better fit depends on your goals.
| NEGG | RXRX | |
|---|---|---|
Market Cap | $398.29M | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $128.09 | $6.79 |
52-Week Low | $12.87 | $2.84 |
Enterprise Value | $397.09M | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $18.99, up 3.32% today, with a bullish technical signal from moving averages. Recent earnings beat expectations, showing improved profitability with a net income margin of 0.39% in 2025, up from negative margins in prior years. The company maintains a low P/S ratio of 0.28, but a high P/E of 73.16 reflects growth expectations. News highlights include AI shopping features and product launches, indicating innovation efforts.
Outlook: NEGG shows operational improvement with narrowing losses, but negative operating cash flow and high valuation multiples pose risks. The sole analyst coverage is bullish, yet investor caution is warranted due to competitive pressures and reliance on tech spending cycles. Upside depends on sustained revenue growth and margin expansion.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
